	US 11,872,240 B2
	Antimicrobial formulations comprising vancomycin or tobramycin
Chander Shekhar, New Delhi (IN)
Assigned to Chander Shekhar, Delhi (IN); Khalid Khan, Delhi (IN); and Shruti Kaushik, Delhi (IN)
Appl. No. 17/266,667
Filed by Chander Shekhar, New Delhi (IN); Khalid Khan, New Delhi (IN); and Shruti Kaushik, New Delhi (IN)
PCT Filed Aug. 6, 2019, PCT No. PCT/IB2019/056683 § 371(c)(1), (2) Date Feb. 8, 2021, PCT Pub. No. WO2020/031083, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 201811029497 (IN), filed on Aug. 6, 2018.
Prior Publication US 2021/0308164 A1, Oct. 7, 2021
Int. Cl. A61K 31/7036 (2006.01); A61K 31/702 (2006.01); A61K 47/10 (2017.01)

CPC A61K 31/7036 (2013.01) [A61K 31/702 (2013.01); A61K 47/10 (2013.01)]

7 Claims

1. A pharmaceutical composition comprising:

an antimicrobial agent or a pharmaceutically acceptable salt thereof or a combination of antimicrobial agents or a pharmaceutically acceptable salts thereof;

a pharmaceutically acceptable carrier; and

at least one excipient;

wherein,

said antimicrobial agent is vancomycin in the range of 5-20 mg or tobramycin in the range of 55-65 mg;

said combination of antimicrobial agents is a mixture of tobramycin, in the range of 55-65 mg, and vancomycin, in the range of 5-20 mg; and

the pharmaceutically acceptable carrier is Vitamin D₃in the range of 1-5 gm;

the Vitamin D₃is loaded with the antimicrobial agent; and

the composition is applied topically for managing the infected open wounds within a time span of 7 days.